Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares

Key Points

• Insider sale: Steven Pieper sold 5,000 Xeris Biopharma shares at $8.50 each, totaling $42,500, under a pre-arranged Rule 10b5-1 plan. He still directly owns 1,356,053 shares.
• Stock and earnings: Xeris shares traded near $8.43, while the company’s latest quarterly EPS loss of $0.18 missed estimates despite revenue of $92.1 million exceeding expectations.
• Analyst outlook: Institutional investors own 42.75% of the company, and analyst views remain mixed, producing an average “Hold” rating with a $12.00 target price.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider directly owned 1,356,053 shares of the company's stock, valued at $11,526,450.50. The trade was a 0.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $42,500.00.
• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS traded down $0.01 during midday trading on Tuesday, reaching $8.43. 1,144,088 shares of the company's stock traded hands, compared to its average volume of 1,849,041. The company has a fifty day simple moving average of $8.32 and a two-hundred day simple moving average of $6.93. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a market cap of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analysts' expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Xeris Biopharma during the second quarter worth approximately $115,042,000. Vanguard Group Inc. grew its holdings in Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company's stock valued at $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company's stock worth $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp increased its stake in shares of Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company's stock worth $32,318,000 after acquiring an additional 378,595 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company's stock worth $26,657,000 after acquiring an additional 185,063 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Weiss Ratings cut Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Barclays lifted their price target on Xeris Biopharma from $9.00 to $12.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. Finally, Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Xeris Biopharma currently has an average rating of "Hold" and an average target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source